Incyte (NASDAQ:INCY) Earns Buy Rating from HC Wainwright

Incyte (NASDAQ:INCY)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $135.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 34.93% from the company’s current price.

A number of other research analysts have also commented on the stock. Weiss Ratings reiterated a “hold (c+)” rating on shares of Incyte in a research note on Thursday, January 22nd. Royal Bank Of Canada raised their price objective on Incyte from $81.00 to $84.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Mizuho set a $121.00 price target on Incyte and gave the company an “outperform” rating in a research report on Monday, December 8th. TD Cowen reissued a “buy” rating on shares of Incyte in a research note on Tuesday, January 13th. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating and set a $107.00 price objective (down from $116.00) on shares of Incyte in a report on Tuesday, January 20th. Nine research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Incyte presently has a consensus rating of “Hold” and an average price target of $103.29.

Incyte Stock Down 8.2%

Shares of Incyte stock opened at $100.05 on Wednesday. Incyte has a 52-week low of $53.56 and a 52-week high of $112.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.13 and a current ratio of 3.20. The business’s 50 day simple moving average is $101.80 and its 200 day simple moving average is $93.78. The firm has a market cap of $19.64 billion, a PE ratio of 16.76, a P/E/G ratio of 0.65 and a beta of 0.82.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, missing analysts’ consensus estimates of $1.96 by ($0.16). Incyte had a net margin of 24.69% and a return on equity of 26.56%. The company had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.35 billion. During the same quarter in the prior year, the business earned $1.43 earnings per share. The firm’s revenue for the quarter was up 27.8% compared to the same quarter last year. On average, analysts predict that Incyte will post 4.86 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Incyte news, insider Thomas Tray sold 2,774 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $100.00, for a total transaction of $277,400.00. Following the completion of the sale, the insider directly owned 22,973 shares in the company, valued at approximately $2,297,300. This trade represents a 10.77% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mohamed Khairie Issa sold 10,856 shares of Incyte stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $109.07, for a total value of $1,184,063.92. Following the completion of the sale, the executive vice president directly owned 66,132 shares of the company’s stock, valued at approximately $7,213,017.24. The trade was a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 95,225 shares of company stock worth $9,519,745. Corporate insiders own 17.80% of the company’s stock.

Institutional Trading of Incyte

Several institutional investors have recently made changes to their positions in the business. NewEdge Advisors LLC grew its holdings in shares of Incyte by 369.3% in the first quarter. NewEdge Advisors LLC now owns 12,597 shares of the biopharmaceutical company’s stock valued at $763,000 after purchasing an additional 9,913 shares in the last quarter. Jones Financial Companies Lllp grew its stake in shares of Incyte by 15.1% in the 1st quarter. Jones Financial Companies Lllp now owns 4,944 shares of the biopharmaceutical company’s stock worth $299,000 after buying an additional 648 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Incyte by 6.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 814,559 shares of the biopharmaceutical company’s stock worth $49,322,000 after buying an additional 48,751 shares in the last quarter. United Services Automobile Association bought a new stake in shares of Incyte in the 1st quarter worth about $219,000. Finally, Focus Partners Wealth lifted its holdings in shares of Incyte by 74.1% in the 1st quarter. Focus Partners Wealth now owns 21,024 shares of the biopharmaceutical company’s stock valued at $1,273,000 after acquiring an additional 8,951 shares during the last quarter. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: H.C. Wainwright reiterated a Buy rating with a $135 price target, citing long-term revenue durability and an underappreciated pipeline, which supports upside potential if pipeline assets progress. Incyte: Long-Term Revenue Durability and Underappreciated Pipeline Support Buy Rating and $135 Target
• Neutral Sentiment: Top-line strength: Q4 revenue of ~$1.51B beat consensus (~$1.35B) and rose ~28% YoY, driven by Jakafi and Opzelura product sales — a positive operating signal even as EPS missed. Earnings Release / Slides
• Neutral Sentiment: Company commentary and the earnings call highlighted pipeline progress and strategic focus beyond Jakafi, which could mitigate long-term risk if clinical readouts are favorable. Earnings Call Highlights
• Negative Sentiment: EPS miss: Q4 EPS $1.80 vs. consensus ~$1.96, which, together with a softer 2026 revenue forecast, pressured sentiment and valuations. Zacks: INCY Q4 Earnings Miss
• Negative Sentiment: Guidance and Jakafi risk: Management’s weak 2026 revenue outlook and commentary that Opzelura may underperform heightens concerns about replacing revenue when Jakafi faces patent expiry/generic competition. This is the main driver of today’s selloff. Reuters: Weak 2026 Forecast
• Neutral Sentiment: Market/coverage notes and transcripts are available (Seeking Alpha, Yahoo) for investors wanting the full call and management commentary to model 2026 scenarios. Earnings Call Transcript Press Release
• Neutral Sentiment: Short-interest data reported appears anomalous (zeros) and is unlikely to explain intra-day moves; focus remains on guidance and product dynamics.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.